Remember meForgot password?
    Log in with Twitter
Press Release
BAVENO, Italy, June 30, 2014--(PR Newswire)--

GrowBLOX™ Sciences, Inc. Represented at International Cannabinoid Research Society Symposium 2014

PR Newswire

BAVENO, Italy, June 30, 2014 /PRNewswire/ -- GrowBLOX™ Sciences, Inc. (OTCQB: GBLX) is represented at the 24th Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS 2014) by their Chief Science Officer and Member of the International Cannabinoid Research Society, Andrea L. Small-Howard, PhD, MBA. GBLX seeks co-development partners from ICRS 2014 to assist in their pursuit of the research, testing, and development of FDA-approved cannabinoid treatment options using the stable profile of phytocannabinoids present in the cannabis plant cultivated in their proprietary GrowBLOX™ controlled indoor growing system. 

ICRS 2014 provides an international forum where the brightest minds in cannabinoid research exchange scientific information on the latest developments in their field. The conference, which is sponsored by GW Pharmaceuticals and other cannabinoid business leaders, also promotes dialogue regarding where cannabinoid therapies are headed in the context of the international political and regulatory environments.

"GBLX is eager to forge solid relationships in the international cannabinoid research and business communities that will facilitate our goal of nurturing a cannabis-based biopharmaceutical pipeline," explains Andrea Small-Howard, CSO and Board Member of GBLX.

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation.  The GrowBLOX™ chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product.  The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. More recently, the Company endeavors to pursue the research, testing, and development of FDA-approved treatment options using the phytocannabinoids extracted from cannabis grown in its GrowBLOX chamber.

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Jonathan Barkman
Riverview Capital Enterprises

SOURCE GrowBLOX Sciences, Inc.

Latest News
Top News